Company Profile

DR. REDDYS LABORATORIES LTD.

NSE : DRREDDYBSE : 500124ISIN CODE : INE089A01023Industry : Pharmaceuticals & DrugsHouse : Dr. Reddy's
BSE2917.00-26.15 (-0.89 % )
PREV CLOSE (Rs.) 2943.15
OPEN PRICE (Rs.) 3017.85
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 21437
TODAY'S LOW / HIGH (Rs.)2848.60 3046.90
52 WK LOW / HIGH (Rs.)2352 3363
NSE2916.50 -32.05 (-1.09 % )
PREV CLOSE(Rs.) 2948.55
OPEN PRICE (Rs.) 2952.80
BID PRICE (QTY) 2916.50 (66 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 801588
TODAY'S LOW / HIGH(Rs.) 2846.10 3046.95
52 WK LOW / HIGH (Rs.)2351.2 3364.95

Company News

Date Heading Details
27-Mar-2020 Dr. Reddy's board approves borrowing of Rs 2,000 crore via multiple routes <p align="justify">Dr. Reddy's Laboratories' Board of Directors has approved borrowings, either through issuance of commercial papers, debentures, bonds and/or through bank credit lines, term loans including external commercial borrowings, as the company may deem fit, up to an aggregate amount of Rs 2,000 crore, in one or more tranches.&nbsp; <p align="justify">Further, the board of directors has also approved sale of the Contract Development and Manufacturing Organisation (CDMO) division of Custom Pharmaceutical Services (CPS) business of the Company, to its wholly owned step-down subsidiary -- Aurigene Pharmaceutical Services (APSL), on slump sale basis, for a consideration of $72 million. <p align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.</p>
25-Mar-2020 Dr. Reddy's Laboratories gains on planning to raise funds through CP <p align="justify">Dr. Reddy's Laboratories is currently trading at Rs. 2865.15, up by 6.50 points or 0.23% from its previous closing of Rs. 2858.65 on the BSE.</p><p align="justify">The scrip opened at Rs. 2858.00 and has touched a high and low of Rs. 2920.00 and Rs. 2797.70 respectively. So far 8333 shares were traded on the counter.</p><p align="justify">The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3363.00 on 20-Feb-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.</p><p align="justify">Last one week high and low of the scrip stood at Rs. 3187.00 and Rs. 2497.60 respectively. The current market cap of the company is Rs. 47856.73 crore.</p><p align="justify">The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.</p><p align="justify">Dr. Reddy's Laboratories is planning to raise funds by issuance of Commercial Paper (CP). The meeting of company's Board of Directors will be held on March 27, 2020 to consider and approve the same.</p><p align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.</p>
24-Mar-2020 Dr. Reddy's Laboratories planning to raise funds through CP <div align="justify">Dr. Reddy's Laboratories is planning to raise funds by issuance of Commercial Paper (CP). The meeting of company's Board of Directors will be held on March 27, 2020 to consider and approve the same.<br><br></div><div align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.<br><br></div>
23-Mar-2020 Dr. Reddy's shines on launching Pyrimethamine Tablets in US Market <p align="justify">Dr. Reddys Laboratories is currently trading at Rs. 2951.85, up by 53.75 points or 1.85% from its previous closing of Rs. 2898.10 on the BSE.</p><p align="justify">The scrip opened at Rs. 2700.00 and has touched a high and low of Rs. 3187.00 and Rs. 2651.00 respectively. </p><p align="justify">The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3363.00 on 20-Feb-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.</p><p align="justify">Last one week high and low of the scrip stood at Rs. 3187.00 and Rs. 2497.60 respectively. The current market cap of the company is Rs. 48158.33 crore.</p><p align="justify">The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.</p><p align="justify">Dr. Reddy's Laboratories has launched Pyrimethamine Tablets USP, 25 mg, a therapeutic equivalent and first-wave generic version of Daraprim (pyrimethamine) Tablets, approved by the U.S. Food and Drug Administration (USFDA). This product is the only ABrated generic version Daraprim (pyrimethamine) Tablets approved by the USFDA.</p><p align="justify">Pyrimethamine is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. The company's Pyrimethamine Tablets USP, are available in 25 mg dose in bottle count sizes of 30 and 100. The Daraprim (pyrimethamine) brand had U.S. sales of approximately $10 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.</p><p align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.<br></p>
20-Mar-2020 Dr. Reddy's launches Pyrimethamine Tablets in US Market <p align="justify">Dr. Reddy's Laboratories has launched Pyrimethamine Tablets USP, 25 mg, a therapeutic equivalent and first-wave generic version of Daraprim (pyrimethamine) Tablets, approved by the U.S. Food and Drug Administration (USFDA). This product is the only ABrated generic version Daraprim (pyrimethamine) Tablets approved by the USFDA.<p align="justify">Pyrimethamine is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. The company's Pyrimethamine Tablets USP, are available in 25 mg dose in bottle count sizes of 30 and 100. The Daraprim (pyrimethamine) brand had U.S. sales of approximately $10 million MAT for the most recent twelve months ending in January 2020 according to IQVIA Health.<p align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.</p>
19-Mar-2020 Dr. Reddy's launches Naloxone Hydrochloride Injection <p align="justify">Dr. Reddy's Laboratories has launched Naloxone Hydrochloride Injection USP, 2 mg/2 ml (1 mg/ml) Single-dose Prefilled Syringe, a therapeutic equivalent generic version of Narcan (naloxone hydrochloride) Injection USP, approved by the U.S. Food and Drug Administration (USFDA).<br></p><p align="justify">The Naloxone Hydrochloride Injection USP, 2 mg/2 ml (1 mg/ml) had U.S. sales of approximately $31 million MAT for the most recent twelve months ending in January 2020. The company's Naloxone Hydrochloride Injection USP, 2 mg/2 ml (1 mg/ml) is available in 2 ml single-dose prefilled syringe.<br></p><p align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.<br></p>
19-Mar-2020 Dr. Reddys Laboratories inform about press release <P align=justify>Dr. Reddys Laboratories has informed that the company has enclosed a Press Release on March 19 2020 tilted ‘Dr. Reddy's Laboratories announces first-to-market launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Singledose Prefilled Syringe in the US Market.'<P align=justify>The above information is a part of company's filings submitted to BSE.&nbsp;<BR>
17-Mar-2020 Dr. Reddy's launches Ziprasidone Mesylate for Injection in US Market <p align="justify">Dr. Reddy's Laboratories has launched Ziprasidone Mesylate for Injection, 20 mg (base)/ml Single-dose Vials, the therapeutic generic equivalent of Geodon (ziprasidone mesylate) Injection, 20 mg/ml, approved by the U.S. Food and Drug Administration (USFDA). According to IQVIA Health, the Geodon brand had U.S. sales of approximately $21.8 million MAT for the most recent twelve months ending in January 2020.<p align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.</p>
17-Mar-2020 Dr. Reddy's gains on launching Ziprasidone Mesylate for Injection in US Market <p align="justify">Dr. Reddy's Laboratories is currently trading at Rs. 2834.40, up by 8.00 points or 0.28% from its previous closing of Rs. 2826.40 on the BSE.<br></p><p align="justify">The scrip opened at Rs. 2800.00 and has touched a high and low of Rs. 2902.00 and Rs. 2800.00 respectively. So far 12898 shares were traded on the counter.<br></p><p align="justify">The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3363.00 on 20-Feb-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.<br></p><p align="justify">Last one week high and low of the scrip stood at Rs. 3083.00 and Rs. 2589.85 respectively. The current market cap of the company is Rs. 47791.92 crore.<br></p><p align="justify">The promoters holding in the company stood at 26.76%, while Institutions and Non-Institutions held 45.14% and 13.80% respectively.<br></p><p align="justify">Dr. Reddy's Laboratories has launched Ziprasidone Mesylate for Injection, 20 mg (base)/ml Single-dose Vials, the therapeutic generic equivalent of Geodon (ziprasidone mesylate) Injection, 20 mg/ml, approved by the U.S. Food and Drug Administration (USFDA). According to IQVIA Health, the Geodon brand had U.S. sales of approximately $21.8 million MAT for the most recent twelve months ending in January 2020.</p><p align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.<br></p>
06-Mar-2020 Dr. Reddy's gets 3 observations from USFDA for API Manufacturing Plant in Telangana <p align="justify">US Food and Drug Administration (USFDA) has completed audit at Dr. Reddy's Laboratories' API Manufacturing Plant-5 at Miryalaguda, Nalgonda District, Telangana. The company has been issued a Form 483 with 3 observations. The company will address them comprehensively within the stipulated timeline. <p align="justify">Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.</p>